Tweetovi

Blokirali ste korisnika/cu @AlbigesL

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AlbigesL

  1. proslijedio/la je Tweet

    The latest issue of is now live Featuring: : MRI-directed biopsy strategies : local surgery in metastatic disease : how to manage renal … and much more! Happy reading!

    , , i još njih 5
    Poništi
  2. 29. sij
    Poništi
  3. 17. pro 2019.

    Congratulations to all ! Major step forward for RCC research and patient care

    Poništi
  4. proslijedio/la je Tweet
    16. pro 2019.

    Prof. Jean-Charles Soria appointed General Director of by the french Minister of Solidarity and Health , for a term of 5 years. Read more ▶️

    Poništi
  5. 29. stu 2019.

    Major debate on the data available in good risk IMDC pts - combination VEGF-IO regimens over single agent TKI in VEGF driven disease ultimately aiming the cure so IO needed

    Poništi
  6. proslijedio/la je Tweet

    The latest issue of is now available for download! Featuring: : RCTs of -targeted vs systematic biopsy : role of variant histology in MIBC : 1st line treatment of mRCC Happy reading!

    , , i još njih 2
    Poništi
  7. 20. stu 2019.

    Important to characterize unconventional/mixed response with IO in mRCC. NIVOREN is the right cohort to expand our understanding of this phenomenon and ultimately understand the biology behind

    Poništi
  8. 19. stu 2019.
    Poništi
  9. 17. stu 2019.

    Many thanks to the staff for their organisation Looking forward Athens

    Poništi
  10. 16. stu 2019.
    Poništi
  11. proslijedio/la je Tweet
    16. stu 2019.

    Current and evolving management of BCG refractory non muscle invasive bladder cancer. Excellent overview by Valrubicin is the only approved agent and clinical trials are preferred. Approval of pembro will change the Rx landscape.

    , , i još njih 4
    Poništi
  12. proslijedio/la je Tweet

    Having give a lecture on RCC prognostic factors during is a jewel. It is like having giving a talk on mRCC clinical trials. Oh...wait...did we have both ??

    Poništi
  13. 11. lis 2019.

    Amazing what Benard ESCUDIER & have achieved together with over these 14 years in the field of mRCC! Role models to all of us Thanks for the picture

    Poništi
  14. 10. lis 2019.

    Kicking off the 8th edition of with biology insight on mRCC evolution from our international guest star seminal work from lab

    Poništi
  15. proslijedio/la je Tweet
    8. lis 2019.

    Le Pr Jean-Yves Blay élu président de la fédération Unicancer

    Poništi
  16. 30. ruj 2019.

    Couldn’t agree more on fantastic coverage of and GU meetings! Thank you Fabio

    Poništi
  17. 29. ruj 2019.

    Proposed (personal opinion) new guidelines for 1st line mRCC by Dr Bernard ESCUDIER

    Poništi
  18. 29. ruj 2019.

    2 more mRCC trials in “immunotherapy of cancer” session to be discussed by Bernard ESCUDIER don’t miss lenva-pembro compelling RR after prior IO exposure !

    Poništi
  19. 29. ruj 2019.

    Starting now GU Poster discussants ready to present new works across RCC/UC/GCT!

    Poništi
  20. 6. ruj 2019.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·